Drug
Sativex
Sativex: highest development phase Phase 3, developed by Almirall, Jazz Pharmaceuticals. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Almirall, Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sativex® NCT01538225 | Phase 3 | Multiple Sclerosis |
| Sativex NCT00675948 | Phase 3 | Pain |
| Sativex® NCT00713817 | Phase 3 | Pain |
| Sativex NCT01812616 | Phase 1/2 | Cancer |
| Sativex NCT01322464 | Phase 1 | Food Effect |
| Sativex® (Treatment A) NCT02325011 | Phase 1 | Healthy Subjects |
Latest
No recent events.
Follow Sativex on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.